223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST
Toledo R, García A, Moreno A, Mirallas O, Galvao V, Casal G, Vieito M, Braña I, Oberoi A, Bardaji M, Keough K, Navarro F, Jimenez J, Olano A, Nuciforo P, Abbott C, Pugh J, Chen R, Boyle S, Garralda E. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST. Annals Of Oncology 2024, 35: s304-s305. DOI: 10.1016/j.annonc.2024.08.2227.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply